The antiplatelet activity of Escherichia coli lipopolysaccharide is mediated through a nitric oxide cyclic GMP pathway

Citation
Jr. Sheu et al., The antiplatelet activity of Escherichia coli lipopolysaccharide is mediated through a nitric oxide cyclic GMP pathway, EUR J HAEMA, 62(5), 1999, pp. 317-326
Citations number
36
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
EUROPEAN JOURNAL OF HAEMATOLOGY
ISSN journal
09024441 → ACNP
Volume
62
Issue
5
Year of publication
1999
Pages
317 - 326
Database
ISI
SICI code
0902-4441(199905)62:5<317:TAAOEC>2.0.ZU;2-S
Abstract
In this study, Escherichia coli LPS dose-dependently (100-500 mu g/ mi) and time-dependently (10-60 min) inhibited platelet aggregation in human and r abbit platelets stimulated by agonists. LPS also dose-dependently inhibited the intracellular Ca2+ mobilization in human platelets stimulated by colla gen. In addition, LPS (200 and 500 mu g/ml) significantly increased the for mation of cyclic GMP but not cyclic AMP in platelets. LPS (200 mu g/ml) sig nificantly increased the production of nitrate within a 10-min incubation p eriod. Furthermore, LPS also dose-dependently inhibited platelet aggregatio n induced by PDBu (30 nmol/l), a protein kinase C activator. These results indicate that the antiplatelet activity of E. coli LPS may be involved in t he activation of a nitric oxide/cyclic GMP pathway in platelets, resulting in inhibition of platelet aggregation. Therefore, LPS-mediated alteration o f platelet function may contribute to bleeding diathesis in septicemic and endotoxemic patients.